Lab members
  • Armando Genazzani
  • Salvatore Terrazzino
  • Dmitry Lim
  • Ambra Grolla
  • Cristina Travelli
  • Sarah Cargnin
  • Simone Torretta
  • Beatrice Riva
  • Roberta Zaninetti
  • Laura Tapella
  •   Research

    Salvatore Terrazzino
    Salvatore Terrazzino


    CURRENT POSITION:                    

    From september 2012- Researcher fixed-term (Scientific Sector: BIO/14), Department of Pharmaceutical Sciences at the Universit del Piemonte Orientale A. Avogadro, Novara, Italy.

    Main research areas of interest:

    - Pharmacogenetics of migraine: identification of genetic polymorphisms as predictive factors for response to triptans in migraine patients, and for migrain progression to Medication Overuse Headache (MOH). Affecting up to 12% of males and 24% of females in the general population, migraine is a primary headache disorder with a profound social and economic impact. The term medication-overuse headache has been recently introduced to describe a chronic daily headache usually occurring in people with migraine or tension-type headaches caused by an excessive use of medication taken for symptomatic headache relief.

    - Radiogenetics in breast cancer: identification of genetic polymorphisms as predictors for acute and late normal tissue toxicity in patients submitted to post-surgical radiotherapy for breast cancer. The identification of relevant gene variants could contribute to the construction of predictive risk models for the occurrence of radiation-induced toxicities in breast cancer patients.

    - Pharmacogenetics of transplantation:  evaluation of the role of genetic variants as predictors of clinical outcome, pharmacokinetics and adverse effects of immunosuppressive drugs in kidney transplant patients. The results of the ongoing pharmacogenetic studies should provide a basis towards the personalization of immunosuppressive drug therapy.

    - Validation of pharmacogenetic markers: conduction of meta-analyses on published data to quantitatively evaluate the impact of genetic variants in response to specific pharmacological treatments. The identification of genetic determinants with proven clinical value should provide the basis for the use of pharmacogenetic testing in clinical practice as tool to improve the safety and efficacy of pharmacological treatments.



    1990 - Degree in Biology Sciences, State University of Milan (Italy).

    1995 - Ph.D in Pharmacology, obtained at "Mario Negri" Research Institute, Milan.

    2006 Advanced Training in Nutrition and Wellness, State University of Milan.


    2008 2012: Post-doctoral position at the Department of Chemical, Food, Pharmaceutical and Pharmacological Sciences (DiSCAFF), Universit del Piemonte Orientale.

    1999 2006: Senior Scientist at Research and Innovation, a private biotech company of Northeast Italy focusing on "Pharmacogenetics" and " in vivo Pharmacology ".

    1996-1999: Post-doctoral position at the INSERM UNIT 334 (Orsay, France), funded by Biomed grant "Training and Mobility of Researchers", contract n: BMH4-CT96-5007.

    1992- 1996: Fellowship at Mario Negri Institute for Pharmacological Research, Milan.

    24DNA Methyltransferase Gene Polymorphisms for Prediction of Radiation-Induced Skin Fibrosis after Treatment of Breast Cancer: A Multifactorial Genetic Approach.
    Terrazzino S(1), Deantonio L(2)(3), Cargnin S(1), Donis L(3), Pisani C(3), Masini L(3), Gambaro G(3), Canonico PL(1), Genazzani AA(1), Krengli M(2)(3).
    Cancer Res Treat. 2017 Apr;49(2):464-472. doi: 10.4143/crt.2016.256. Epub 2016 Aug 23.
    [Show abstract ]  
    23Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
    Travelli C(1), Aprile S(1), Rahimian R(2)(3), Grolla AA(1), Rogati F(1), Bertolotti M(1), Malagnino F(1), di Paola R(4), Impellizzeri D(4), Fusco R(4), Mercalli V(1), Massarotti A(1), Stortini G(5), Terrazzino S(1), Del Grosso E(1), Fakhfouri G(2), Troiani MP(6), Alisi MA(6), Grosa G(1), Sorba G(1), Canonico PL(1), Orsomando G(7), Cuzzocrea S(4), Genazzani AA(1), Galli U(1), Tron GC(1).
    J Med Chem. 2017 Mar 9;60(5):1768-1792. doi: 10.1021/acs.jmedchem.6b01392. Epub 2017 Feb 22.
    [Show abstract ]  
    22Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis.
    Cargnin S(1), Canonico PL(1), Genazzani AA(1), Terrazzino S(2).
    J Thorac Oncol. 2017 Jan;12(1):43-53. doi: 10.1016/j.jtho.2016.08.002. Epub 2016 Aug 16.
    [Show abstract ]  
    21Pilot cohort study on the potential role of TCF7L2 rs7903146 on ischemic heart disease among non-diabetic kidney transplant recipients.
    Quaglia M(1), Musetti C(1), Merlotti G(1), Genazzani AA(2), Cargnin S(2), Cena T(3), Cantaluppi V(1), Terrazzino S(2).
    Clin Transplant. 2017 Jun;31(6). doi: 10.1111/ctr.12959. Epub 2017 Apr 17.
    [Show abstract ]  
    20The Role of TCF7L2 rs7903146 in Diabetes After Kidney Transplant: Results From a Single-Center Cohort and Meta-Analysis of the Literature.
    Quaglia M(1), Terrazzino S, Musetti C, Cargnin S, Merlotti G, Cena T, Stratta P, Genazzani A.
    Transplantation. 2016 Aug;100(8):1750-8. doi: 10.1097/TP.0000000000000978.
    [Show abstract ]  
    19Common European Mitochondrial Haplogroups in the Risk for Radiation-induced Subcutaneous Fibrosis in Breast Cancer Patients.
    Terrazzino S(1), Deantonio L(2), Cargnin S(1), Donis L(3), Pisani C(3), Masini L(3), Gambaro G(3), Canonico PL(1), Genazzani AA(1), Krengli M(4).
    Clin Oncol (R Coll Radiol). 2016 Mar 9. pii: S0936-6555(16)00084-4. doi: 10.1016/j.clon.2016.02.007. [Epub ahead of print]
    [Show abstract ]  
    18The Role of TCF7L2 rs7903146 in Diabetes After Kidney Transplant: Results From a Single-Center Cohort and Meta-Analysis of the Literature.
    Quaglia M(1), Terrazzino S, Musetti C, Cargnin S, Merlotti G, Cena T, Stratta P, Genazzani A.
    Transplantation. 2015 Nov 21. [Epub ahead of print]
    [Show abstract ]  
    17Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache.
    Cargnin S(1), Viana M, Sances G, Bianchi M, Ghiotto N, Tassorelli C, Nappi G, Canonico PL, Genazzani AA, Terrazzino S.
    Eur J Clin Pharmacol. 2014 Oct;70(10):1195-202. doi: 10.1007/s00228-014-1726-6. Epub 2014 Aug 7.
    [Show abstract ]  
    16Triptan use in Italy: Insights from administrative databases.
    Da Cas R(1), Nigro A(2), Terrazzino S(3), Sances G(4), Viana M(4), Tassorelli C(4), Nappi G(4), Cargnin S(3), Pisterna A(2), Traversa G(1), Genazzani AA(5).
    Cephalalgia. 2014 Sep 22. pii: 0333102414550419.
    [Show abstract ]  
    15Functional polymorphisms in COMT and SLC6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy.
    Cargnin S(1), Viana M, Ghiotto N, Bianchi M, Sances G, Tassorelli C, Nappi G, Canonico PL, Genazzani AA, Terrazzino S.
    Eur J Neurol. 2014 Jul;21(7):989-95. doi: 10.1111/ene.12424. Epub 2014 Mar 29.
    [Show abstract ]  
    14Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
    Cargnin S(1), Jommi C, Canonico PL, Genazzani AA, Terrazzino S.
    Pharmacogenomics. 2014 May;15(7):963-76. doi: 10.2217/pgs.14.52.
    [Show abstract ]  
    13Pharmacogenomics of episodic migraine: time has come for a step forward.
    Viana M(1), Terrazzino S, Genazzani AA, Grieco GS, Cargnin S, Santorelli FM, Pierelli F, Tassorelli C, Nappi G, Di Lorenzo C.
    Pharmacogenomics. 2014 Mar;15(4):541-9. doi: 10.2217/pgs.14.20.
    [Show abstract ]  
    12DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.
    Terrazzino S(1), Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA.
    Pharmacogenomics. 2013 Aug;14(11):1255-72. doi: 10.2217/pgs.13.116.
    [Show abstract ]  
    11Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study.
    Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, Terrazzino S, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Psaromyalou A, Angelopoulou A, Kalofonos HP.
    Cancer. 2013 Jul 2. doi: 10.1002/cncr.28234.
    [Show abstract ]  
    10An Opposite-Direction Modulation of the COMT Val158Met Polymorphism on the Clinical Response to Intrathecal Morphine and Triptans.
    Cargnin S, Magnani F, Viana M, Tassorelli C, Mittino D, Cantello R, Sances G, Nappi G, Canonico PL, Genazzani AA, Raffaeli W, Terrazzino S.
    J Pain. 2013 Jun 14. pii: S1526-5900(13)00968-1. doi: 10.1016/j.jpain.2013.04.006. [Epub ahead of print]
    [Show abstract ]  
    9Severe acute nephrotoxicity in a kidney transplant patient despite low tacrolimus levels: a possible interaction between donor and recipient genetic polymorphisms.
    Quaglia M, Terrazzino S, Boldorini R, Stratta P, Genazzani AA.
    J Clin Pharm Ther. 2013 Apr 9. doi: 10.1111/jcpt.12066.
    [Show abstract ]  
    8Triptan nonresponders: Do they exist and who are they?
    Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ.
    Cephalalgia. 2013 Apr 5.
    [Show abstract ]  
    7The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis.
    Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA.
    Pharmacogenet Genomics. 2012 Aug;22(8):642-5. doi: 10.1097/FPC.0b013e3283557c74.
    [Show abstract ]  
    6Common variants of eNOS and XRCC1 genes may predict acute skin toxicity in breast cancer patients receiving radiotherapy after breast conserving surgery.
    Terrazzino S, Mattina PL, Masini L, Caltavuturo T, Gambaro G, Canonico PL, Genazzani AA, Krengli M.
    Radiother Oncol. 2012 Jan 14.
    [Show abstract ]  
    5The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation.
    Stratta P, Quaglia M, Cena T, Antoniotti R, Fenoglio R, Menegotto A, Ferrante D, Genazzani A, Terrazzino S, Magnani C.
    Eur J Clin Pharmacol. 2011 Nov 20.
    [Show abstract ]  
    4Common Variants of GSTP1, GSTA1, and TGFβ1 are Associated with the Risk of Radiation-Induced Fibrosis in Breast Cancer Patients.
    Terrazzino S, La Mattina P, Gambaro G, Masini L, Franco P, Canonico PL, Genazzani AA, Krengli M.
    Int J Radiat Oncol Biol Phys. 2011 Nov 11.
    [Show abstract ]  
    3Association of haplotype combination of serotonin transporter gene polymorphisms with monthly headache days in MOH patients.
    Terrazzino S, Tassorelli C, Sances G, Allena M, Viana M, Monaco F, Bellomo G, Nappi G, Canonico PL, Genazzani AA.
    Eur J Neurol. 2011 May 18.
    [Show abstract ]  
    2Role of 2 common variants of 5HT2A gene in medication overuse headache.
    Terrazzino S, Sances G, Balsamo F, Viana M, Monaco F, Bellomo G, Martignoni E, Tassorelli C, Nappi G, Canonico PL, Genazzani AA.
    Headache. 2010 Nov;50(10):1587-96. doi: 10.1111/j.1526-4610.2010.01757.x. Epub 2010 Aug 27.
    [Show abstract ]  
    1The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients.
    Terrazzino S, Viana M, Floriddia E, Monaco F, Mittino D, Sances G, Tassorelli C, Nappi G, Rinaldi M, Canonico PL, Genazzani AA.
    Eur J Pharmacol. 2010 Sep 1;641(2-3):82-7. Epub 2010 May 18.
    [Show abstract ]  

    Website maintained by Dmitry Lim